Prospective, randomized, investigator-blind trial to evaluate the bacteriologic eradication, safety and tolerability, and pharmacokinetics of different dosages of faropenem medoxomil BID for 10 Days in the treatment of acute otitis media

Trial Profile

Prospective, randomized, investigator-blind trial to evaluate the bacteriologic eradication, safety and tolerability, and pharmacokinetics of different dosages of faropenem medoxomil BID for 10 Days in the treatment of acute otitis media

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2008

At a glance

  • Drugs Faropenem medoxomil (Primary)
  • Indications Bacterial infections; Otitis media
  • Focus Therapeutic Use
  • Sponsors Cardiovascular Systems
  • Most Recent Events

    • 29 Mar 2007 Interim results have been reported.
    • 22 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top